Mirtazapin Biomo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Biomo, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral formulation for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and conforms to European Union pharmaceutical standards for prescription medicines.

GNH USA supplies Mirtazapin Biomo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and logistics support for global healthcare providers. The company adheres to WHO‑GMP guidelines and offers flexible order volumes.

Mirtazapine, marketed as Mirtazapin Biomo, is indicated for depressive disorders that involve serotonergic and noradrenergic dysregulation.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients. - Depression with insomnia: reduces nighttime awakenings and promotes restorative sleep. - Depression with anxiety: helps decrease anxiety symptoms alongside mood improvement. - Treatment‑resistant depression (adjunct): may be added when first‑line agents are insufficient. - Depressive episodes in bipolar disorder (adjunct): used under specialist supervision when needed.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or somnolence - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal ideation or worsening depression - Severe hypotension or syncope - Hepatic dysfunction - Seizures (rare)

When prescribing Mirtazapine, clinicians should consider several safety measures. - Hepatic function: assess liver status before initiating therapy. - Mood monitoring: watch for worsening depression or emergent suicidal thoughts. - Elderly patients: use caution due to increased risk of sedation and falls. - Discontinuation: avoid abrupt cessation to reduce withdrawal phenomena. - Concomitant CNS depressants: evaluate additive sedative effects. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic antidepressants (e.g., SSRIs, SNRIs): may increase serotonin toxicity. - Potent CYP3A4 inhibitors (e.g., ketoconazole): can raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Alcohol: enhances central nervous system depression. - Antihistamines: additive sedation. - CNS depressants (benzodiazepines, opioids): increased drowsiness. - CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy. - Warfarin: monitor INR for potential anticoagulant effect changes.